Современные подходы к терапии псориаза у детей с учетом особенностей коморбидного фона
Аннотация
Ключевые слова
Литература
Augustin M., Glaeske G., Radtke M.A. et al. Epidemiology
and comorbidity of psoriasis in children. Br. J. Dermat. 2010;
(3): 633–636.
Tollefson M.M., Crowson C.S., McEvoy M.T., Maradit
Kremers H. Incidence of psoriasis in children: a populationbased
study. J. Am. Acad. Dermatol. 2010; 62(6): 979–987.
Мурашкин Н.Н., Амбарчян Э.Т., Материкин А.И.,
Епишев Р.В. Тяжелые формы псориаза в детском возрас-
те. Фарматека. 2016; 11(324): 34-39 [Murashkin N.N.,
Ambarchian E.T., Materikin A.I., Epishev R.V. Severe psoriasis
in children. Pharmateca. 2016; 11(324): 34-39].
De Jager M.E., De Jong E.M., Evers A.W. et al. The
burden of childhood psoriasis. Pediatr. Dermatol. 2011; 28(6):
–737.
Paller A.S., Mercy K., Kwasny M.J. et al. Association of
pediatric psoriasis severity with excess and central adiposity: an
international cross-sectional study. J.A.M.A. Dermatol. 2013;
(2): 166–176.
De Jager M.E., Van de Kerkhof P.C., De Jong E.M.,
Seyger M.M. Epidemiology and prescribed treatments in
childhood psoriasis: a survey among medical professionals. J.
Dermatol. Treat. 2009; 20(5): 254–258.
Matusiewicz D., Koerber A., Schadendorf D. et al.
Childhood psoriasis—an analysis of German health insurance
data. Pediatr. Dermatol. 2014; 31(1): 8–13.
Gelfand J.M., Weinstein R., Porter S.B. et al. Prevalence
and treatment of psoriasis in the United Kingdom: a populationbased
study. Arch. Dermatol. 2005; 141(12): 1537–1541.
Chen G.Y., Cheng Y.W., Wang C.Y. et al. Prevalence
of skin diseases among schoolchildren in Magong, Penghu,
Taiwan: a community-based clinical survey. J. Form. Med. Ass.
Taiwan yi zhi. 2008; 107(1): 21–29.
Griffiths C.E., Barker J.N. Pathogenesis and clinical
features of psoriasis. Lancet. 2007; 370(9583): 263–271.
Tsankov N., Angelova I., Kazandjieva J. Drug-induced
psoriasis. Recognition and management. Am. J. Clin. Dermatol.
; 1(3): 159–165.
Cullen G., Kroshinsky D., Cheifetz A.S., Korzenik J.R.
Psoriasis associated with anti-tumour necrosis factor therapy in
inflammatory bowel disease: a new series and a review of 120
cases from the literature. Aliment. Pharmacol. Ther. 2011;
(11–12): 1318–1327.
Tollefson M.M. Diagnosis and management of psoriasis
in children. Pediatr. Clin. North. Am. 2014; 61(2): 261–277.
Mercy K., Kwasny M., Cordoro K.M. et al. Clinical
manifestations of pediatric psoriasis: results of a multicenter
study in the United States. Pediatr. Dermatol. 2013; 30(4):
–428.
Dermatol. 2008; 24: 125-169.
Becker L., Tom W.L., Eshagh K. et al. Excess adiposity
preceding pediatric psoriasis. J.A.M.A. Dermatol. 2014; 150(5):
–574.
Barisic-Drusko V., Rucevic I. Psoriasis in childhood.
Coll. Anthropol. 2004; 1: 211-285.
Osier E., Wang A.S., Tollefson M.M. et al. Pediatric
psoriasis comorbidity screening guidelines. J.A.M.A. Dermatol.
; 153: 698-704.
National Psoriasis Foundation. Psoriasis and Children
Issue Brief. Available at https://www.psoriasis.org/sites/default/
les/advocacy/Psoriasis and Children Issue Brief one pager.pdf
Au S.C., Goldminz A.M., Loo D.S. et al. Association
between pediatric psoriasis and the metabolic syndrome. J. Am.
Acad. Dermatol. 2012; 66: 1012-1013.
Gottlieb A.B., Chao C., Dann F. Psoriasis comorbidities.
J. Dermatol. Treat. 2008; 19: 5-21.
Tom W.L., Playford M.P., Admani A. et al.
Characterization of lipoprotein composition and function in
pediatric psoriasis reveals a more atherogenic profile. J. Invest.
Dermatol. 2016; 136: 67-73.
Kimball A.B., Wu E.Q., Guerin A. et al. Risks of developing
psychiatric disorders in pediatric patients with psoriasis. J. Am.
Acad. Dermatol. 2012; 67(4): 651–657 (e1–2).
Ogdie A., Weiss P. Epidemiology of psoriatic arthritis.
Rheum. Dis. Clin. North. Am. 2015; 41: 545-568.
Серов Д.Н., Круглова Л.С. Комбинированные мето-
ды системной иммуносупрессивной терапии у пациентов с
тяжелыми формами псориаза и коморбидной патологией.
Физиотерапевт. 2016; 5: 28-34 [Serov D.N., Kruglova L.S.
Combined methods of systemic immunosuppressive therapy in
patients with severe forms of psoriasis and comorbid pathology.
Physical therapist. 2016; 5: 28-34].
Bronckers I.M.G.J., Seyger M.M.B., West D.P. et al.
Safety of systemic agents in pediatric psoriasis: an international
multicenter study. J.A.M.A. Dermatol. 2017; 153: 1147.
Мурашкин Н.Н., Амбарчян Э.Т., Материкин А.И.,
Епишев Р.В. Эффективность терапии тяжелых форм
псориаза у детей с применением низких доз метотрекса-
та в сочетании с узкополосной фототерапией (uvb 311
нм). Вопросы современной педиатрии. 2016; 15(S1): 196
[Murashkin N.N., Ambarchian E.T., Materikin A.I., Epishev
R.V. the Effectiveness of treatment of severe forms of psoriasis in
children with the use of low doses of methotrexate in combination
with narrowband UVB phototherapy (uvb 311 nm). Issues of
modern Pediatrics. 2016; 15(S1): 196].
Мурашкин Н.Н., Понич Е.С., Амбарчян Э.Т. Уль-
трафиолетовая терапия у детей: современные рекоменда-
ции по применению у больных псориазом. Физиотерапевт.
; 6: 24-33 [Murashkin N.N., Panic E.S., E.T. Abarcan
Ultraviolet therapy in children: current recommendations for use
in patients with psoriasis. Physiotherapist. 2015; 6: 24-33].
Потекаев Н.Н., Круглова Л.С. Псориатическая бо-
лезнь. М.: МДВ. 2014. 264 с. [Potekaev N.N., Kruglova L.S.
Psoriatic disease. M.: MDV. 2014. 264 p.].
Росете-Пидаль Е.А., Круглова Л.С., Понич Е.С.,
Чорбинская С.А., Филатова Е.В Лечение больных псориа-
зом с сопутствующим метаболическим синдромом препа-
ратами биологической терапии: предикторы эффектив-
ности и потенциальные риски (Обзор литературы). Ме-
дицина труда и промышленная экология. 2017; 8: 33-36
[Rosete-Pedal E.A., Kruglova L.S., Panich E.S., Chorbinskaya
S.A., Filatov E.V. In the Treatment of patients with psoriasis
with concomitant metabolic syndrome drugs biological therapy:
predictors of effectiveness and potential risks (literature Review).
Occupational medicine and industrial ecology. 2017; 8: 33-36].
Соколовский Е.В., Круглова Л.С., Понич Е.С Ме-
тоды фототерапии в рекомендациях по ведению паци-
ентов с тяжелыми формами псориаза. Физиотерапевт.
; 2: 70-75 [Sokolovsky E.V., Kruglova L.S., E. Panic With
Methods of phototherapy in the guidelines for the management of
patients with severe forms of psoriasis. Physical therapist. 2016;
: 70-75].
Langley R.G., Paller A.S., Herbert A.A. et al. Patientreported
outcomes in pediatric patients with psoriasis undergoing
etanercept treatment: 12-week results from a phase III
randomized controlled trial. J. Am. Acad. Dermatol. 2011; 64:
-70.
Papp K., Thaci D., Marcoux D. et al. Efficacy and
safety of adalimumab every other week versus methotrexate once
weekly in children and adolescents with severe chronic plaque
psoriasis: a randomized, double-blind, phase 3 trial. Lancet.
; 390: 40-49.
Tsang V., Dvorakova V., Enright F. et al. Successful
use of infliximab as first line treatment for severe childhood
generalized pustular psoriasis. J. Eur. Acad. Dermatol. Venereol.
; 30: e1117-e1119.
AbuHilal M., Ho N. Successful treatment of severe
psoriasis in an adolescent with ustekinumab. Pediatr. Dermatol.
; 32: 377-380.
Landells I., Marano Colleen, Hsu M.C. et al.
Ustekinumab in adolescent patients age 12 to 17 years with
moderate-to-severe plaque psoriasis: results of the randomized
phase 3 CADMUS study. J. Am. Acad. Dermatol. 2015; 73:
-603.
Cordoro K.M., Hitraya-Low M., Taravati K. et al.
Skin-infiltrating, interleukin-22-producing T cells differentiate
pediatric psoriasis from adult psoriasis. J. Am. Acad. Dermatol.
; 77: 417-424.
Ссылки
- На текущий момент ссылки отсутствуют.
ISSN 1818-460Х
Зарегистрирован в Министерстве печати и информации РФ 19.03.1998, перерегистрирован 18.11.2005. ПИ № ФС 77-22382
Подписной индекс в каталоге Роспечати 36300